ProMIS Neurosciences Valor contable por acción
¿Qué es el Valor contable por acción de ProMIS Neurosciences?
El Valor contable por acción de ProMIS Neurosciences, Inc. es 0.53
¿Cuál es la definición de Valor contable por acción?
El valor en libros por acción es el activo de una empresa menos el pasivo dividido por el número de acciones en circulación.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Valor contable por acción de compañías en Sector Health Care en TSX en comparadas con ProMIS Neurosciences
¿Qué hace ProMIS Neurosciences?
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Empresas con valor contable por acción similar a ProMIS Neurosciences
- Justin Allen tiene Valor contable por acción de 0.52
- Biofrontera AG tiene Valor contable por acción de 0.52
- Shrenik tiene Valor contable por acción de 0.52
- Ngm Biopharmaceuticals Inc tiene Valor contable por acción de 0.52
- ScoZinc Mining tiene Valor contable por acción de 0.52
- EFT Solutions tiene Valor contable por acción de 0.52
- ProMIS Neurosciences tiene Valor contable por acción de 0.53
- DATATRAK International tiene Valor contable por acción de 0.53
- China MeiDong Auto tiene Valor contable por acción de 0.53
- Alibaba Health Information Technology tiene Valor contable por acción de 0.53
- Bamboos Health Care tiene Valor contable por acción de 0.53
- Interbit tiene Valor contable por acción de 0.53
- Air France-KLM SA tiene Valor contable por acción de 0.53